Anterogen.Co.,Ltd.

KOSDAQ:A065660 Stock Report

Market Cap: ₩151.5b

Anterogen.Co.Ltd Past Earnings Performance

Past criteria checks 0/6

Anterogen.Co.Ltd has been growing earnings at an average annual rate of 10.6%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 2.5% per year.

Key information

10.58%

Earnings growth rate

11.61%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate2.53%
Return on equity-1.86%
Net Margin-19.33%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article • May 30

We're Not Very Worried About Anterogen.Co.Ltd's (KOSDAQ:065660) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Dec 01

We're Hopeful That Anterogen.Co.Ltd (KOSDAQ:065660) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Apr 04

Does Anterogen.Co.Ltd (KOSDAQ:065660) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Feb 05

Health Check: How Prudently Does Anterogen.Co.Ltd (KOSDAQ:065660) Use Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article • Dec 14

Does Anterogen.Co.Ltd's (KOSDAQ:065660) Share Price Gain of 25% Match Its Business Performance?

It hasn't been the best quarter for Anterogen.Co.,Ltd. ( KOSDAQ:065660 ) shareholders, since the share price has fallen...

Revenue & Expenses Breakdown

How Anterogen.Co.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A065660 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 268,057-1,5571,6123,274
31 Dec 257,536-1,3741,6263,091
30 Sep 257,321-1,9111,6603,826
30 Jun 257,181-1,9921,6424,051
31 Mar 257,003-2,4201,7464,325
31 Dec 246,933-2,2931,8634,107
30 Sep 246,953-1,4411,8603,695
30 Jun 246,659-2,3142,0934,147
31 Mar 246,490-3,4501,9865,258
31 Dec 236,500-2,8411,8085,384
30 Sep 236,288-3,2281,8115,763
30 Jun 236,233-3,7031,6405,598
31 Mar 236,467-4,1921,9304,561
31 Dec 226,591-6,8372,0324,658
30 Sep 227,538-6,4522,0204,488
30 Jun 227,793-5,3472,0934,352
31 Mar 228,304-3471,8754,300
31 Dec 218,122-5541,7934,194
30 Sep 216,585-1,3398654,904
30 Jun 215,873491,3843,928
31 Mar 214,732-6,2261,2924,154
31 Dec 204,151-4,3751,2694,007
30 Sep 204,177-6,7052,0663,255
30 Jun 204,169-8,1651,5483,690
31 Mar 204,065-4,1861,7442,994
31 Dec 194,148-4,0501,8302,533
30 Sep 193,9071,0931,4762,860
30 Jun 193,6613591,7102,425
31 Mar 193,560-1,5221,9581,936
31 Dec 183,607-9621,9221,870
30 Sep 183,765-3,0302,442787
30 Jun 184,328-1,4512,135787
31 Mar 184,446-4481,8031,225
31 Dec 175,3574471,7601,305
30 Sep 175,2841631,7821,398
30 Jun 175,066-1031,6941,740
31 Mar 174,757-1541,6191,715
31 Dec 164,8963721,5991,545
30 Sep 164,8138711,5161,061
30 Jun 165,0011,3481,400915
31 Mar 164,9861,3371,1061,152
31 Dec 153,532-581,294908
30 Sep 153,241-4911,3101,241

Quality Earnings: A065660 is currently unprofitable.

Growing Profit Margin: A065660 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A065660 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.6% per year.

Accelerating Growth: Unable to compare A065660's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A065660 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).

Return on Equity

High ROE: A065660 has a negative Return on Equity (-1.86%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/21 12:54
End of Day Share Price 2026/08/21 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anterogen.Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.